High-dose 131 I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan

ConclusionsHigh-dose131I-MIBG therapy in patients with refractory or relapsed high-risk NBL can provide a favorable prognosis without severe nonhematological toxicities. Better prognosis may be anticipated in patients with the initial good response, no pain at131I-MIBG therapy, no VMA and HVA elevation at131I-MIBG therapy, low Curie score (<  16) just before131I-MIBG therapy, and short time interval (<  3 years) between the initial diagnosis and131I-MIBG therapy.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research